• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Scientific-Atlanta

Scientific-Atlanta

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. The Market Turbulence Trap

    This article represents opinions of the author and not those of his firm and are subject to change from time to time and do not constitute a recommendation to purchase and sale any security nor to engage in any particular investment strategy. The information contained here has been obtained from ...

  2. How Money Can Buy Happiness

    This article represents opinions of the author and not those of his firm and are subject to change from time to time and do not constitute a recommendation to purchase and sale any security nor to engage in any particular investment strategy. The information contained here has been obtained from ...

  3. Shockwave Medical Announces $40 Million in Funding for Novel Lithoplasty System to Treat Advanced Peripheral, Coronary Vascular and Aortic Valve Disease

    Shockwave Medical Announces $40 Million in Funding for Novel Lithoplasty System to Treat Advanced Peripheral, Coronary Vascular and Aortic Valve Disease

  4. VimpelCom Reports Continued Operational Improvements And Increased EPS In 1Q15 Results - On Track To Deliver 2015 Targets

    VimpelCom Reports Continued Operational Improvements And Increased EPS In 1Q15 Results - On Track To Deliver 2015 Targets

  5. What Tech Can’t Replace

    This article represents opinions of the author and not those of his firm and are subject to change from time to time and do not constitute a recommendation to purchase and sale any security nor to engage in any particular investment strategy. The information contained here has been obtained from ...

  6. The Wall of Un-Worry

    This article represents opinions of the author and not those of his firm and are subject to change from time to time and do not constitute a recommendation to purchase and sale any security nor to engage in any particular investment strategy. The information contained here has been obtained from ...

  7. New Data Evaluating The Boston Scientific Eluvia™ Drug-Eluting Vascular Stent System Demonstrate 94.4 Percent Primary Patency Rate At Nine Months

    New Data Evaluating The Boston Scientific Eluvia™ Drug-Eluting Vascular Stent System Demonstrate 94.4 Percent Primary Patency Rate At Nine Months

  8. Fixing the Stock-Bond Balance

    This article represents opinions of the author and not those of his firm and are subject to change from time to time and do not constitute a recommendation to purchase and sale any security nor to engage in any particular investment strategy. The information contained here has been obtained from ...

  9. The Upside of Rate Hikes

    This article represents opinions of the author and not those of his firm and are subject to change from time to time and do not constitute a recommendation to purchase and sale any security nor to engage in any particular investment strategy. The information contained here has been obtained from ...

  10. Investing’s Goal: Ownership

    Cisco CSCO started off its fiscal year with a bang, reporting results that exceeded expectations across every metric. We believe Cisco's competitive positioning is getting stronger. For the past two quarters, the company has gained share in almost every one of its markets, and we believe the ...

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.